Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $12.39, but opened at $13.33. SELLAS Life Sciences Group shares last traded at $13.7840, with a volume of 5,370,872 shares.
Analyst Upgrades and Downgrades
SLS has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Tuesday, April 21st. Maxim Group increased their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Stock Analysis on SELLAS Life Sciences Group
SELLAS Life Sciences Group Trading Down 4.5%
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.
Institutional Investors Weigh In On SELLAS Life Sciences Group
A number of large investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC acquired a new position in SELLAS Life Sciences Group during the fourth quarter worth about $26,000. BNP Paribas Financial Markets grew its position in shares of SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after purchasing an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. Finally, California State Teachers Retirement System raised its position in shares of SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares during the last quarter. 17.38% of the stock is owned by institutional investors and hedge funds.
SELLAS Life Sciences Group Company Profile
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.
The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.
Featured Stories
- Five stocks we like better than SELLAS Life Sciences Group
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
